203 related articles for article (PubMed ID: 29473382)
1. A randomized, multicenter, controlled study, comparing efficacy and safety of a new complementary and alternative medicine (CAM) versus Solifenacin Succinate in women with overactive bladder syndrome.
Vecchioli-Scaldazza C; Morosetti C; Maruccia S; Casellato S; Rociola W; Illiano E; Garofalo F
Arch Ital Urol Androl; 2017 Dec; 89(4):296-300. PubMed ID: 29473382
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of a complementary and alternative medicine based on vitamins, herbal products, and amino acid as a first line treatment in idiopathic overactive bladder syndrome in men and women without bladder outlet obstruction.
Morselli S; Gemma L; Liaci A; Campi R; Serni S; Li Marzi V
Urologia; 2022 Aug; 89(3):358-362. PubMed ID: 35176933
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
[TBL] [Abstract][Full Text] [Related]
7. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study.
Vecchioli-Scaldazza C; Morosetti C; Berouz A; Giannubilo W; Ferrara V
Gynecol Obstet Invest; 2013; 75(4):230-4. PubMed ID: 23548260
[TBL] [Abstract][Full Text] [Related]
8. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
[TBL] [Abstract][Full Text] [Related]
9. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
Schiavi MC; Faiano P; D'Oria O; Zullo MA; Muzii L; Benedetti Panici P
J Obstet Gynaecol Res; 2018 Mar; 44(3):524-531. PubMed ID: 29271106
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
Chua ME; See MC; Esmeňa EB; Balingit JC; Morales ML
Low Urin Tract Symptoms; 2018 May; 10(2):135-142. PubMed ID: 28150436
[TBL] [Abstract][Full Text] [Related]
12. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER
Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
[TBL] [Abstract][Full Text] [Related]
13. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study.
Jiang F; Zhu L; Xu T; Gong MY; Huang YL; Li HF; Wang JJ; Tong XW; Cheng XX; Bai WP; Li X; Xu XX; Xu HC
Menopause; 2016 Apr; 23(4):451-7. PubMed ID: 26757270
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.
Zesiewicz TA; Evatt M; Vaughan CP; Jahan I; Singer C; Ordorica R; Salemi JL; Shaw JD; Sullivan KL;
Parkinsonism Relat Disord; 2015 May; 21(5):514-20. PubMed ID: 25814050
[TBL] [Abstract][Full Text] [Related]
17. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.
Lee SD; Chung JM; Kang DI; Ryu DS; Cho WY; Park S
J Korean Med Sci; 2017 Feb; 32(2):329-334. PubMed ID: 28049246
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months.
Vecchioli-Scaldazza C; Morosetti C
Int Braz J Urol; 2018; 44(1):102-108. PubMed ID: 29064651
[TBL] [Abstract][Full Text] [Related]
20. Has the cost of anti-muscarinic a key role in the success rate of patients diagnosed with overactive bladder syndrome?
Vecchioli Scaldazza C; Morosetti C; Pace G; Azizi B; Giannubilo W; Ferrara V
Arch Ital Urol Androl; 2012 Jun; 84(2):68-73. PubMed ID: 22908774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
